Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States

Korábbi kezelés

• Parents of index children with any of the following clinical characteristics will be excluded from the study:
  • KMT2A-R (formerly MLL-R) not receiving ALL therapy
  • Mixed-phenotype acute leukemia (MPAL) not receiving ALL therapy
  • Burkitt's leukemia

• All Children's Oncology Group (COG) NCI Community Oncology Research Program (National Cancer Institute [N]CORP) institutions are eligible for participation in this study upon first parent enrollment
• Parents of an index child who meets the following characteristics are eligible for this study:
  • Index child must be newly diagnosed with de novo ALL
  • Index child must be between the ages of 1 and 14.9 years at the time of the parent's enrollment
  • At the parent's entry to the study, the index child must be receiving induction chemotherapy for newly diagnosed ALL at the enrolling institution. The index child may be enrolled in therapeutic clinical ALL trials or receiving ALL therapy per standard of care
• Parents age 18 years and above are eligible for this study
• Parent must speak English or Spanish in order to participate in the consent process and provide consent. The parent's language skills must be sufficient to understand the study requirements and complete the survey and interview questions
• At the parent's entry to the study, the index child must be receiving induction chemotherapy for newly diagnosed ALL at the enrolling institution. The index child may be enrolled in therapeutic clinical ALL trials or receiving ALL therapy per standard of care
• REGULATORY REQUIREMENTS: All parents must sign a written informed consent for their participation in the study
• REGULATORY REQUIREMENTS: All institutional and NCI requirements for human studies must be met